About | Free Trial

Last Update

2010-12-29T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong David Kleinman?

Dr. David Kleinman M. MD MBA

President

Eyeon Therapeutics

Email: d***@***.com

Eyeon Therapeutics

Background Information

Employment History

Associate Professor of Ophthalmology
Flaum Eye Institute

Associate Professor of Ophthalmology (Part Time)
Flaum Eye Institute at the University of Rochester

Chief Medical Officer
ONL Therapeutics

Chief Executive Officer
Eyeon Particle Sciences LLC

Chief of Ophthalmology
Denver Health

Education

BA

Brown University

Dean's Scholar

Simon School of Business

M.B.A.

M.D.

The University of Rochester Eye Institute

M.D.

University of Rochester Eye Institute - Donald Grover

M.D. with honors

University of Colorado School of Medicine

MBA

Simon School of Business

medical degree with honors

University of Colorado School of Medicine

Web References (87 Total References)


David Kleinman, M.D., ...

www.lumetrics.com, $reference.date [cached]

David Kleinman, M.D., president of Eyeon Therapeutics, and a retinal specialist on FEI's faculty, has been actively involved in moving this promising technology forward.


David Kleinman, Associate ...

ois.net, $reference.date [cached]

David Kleinman, Associate Professor of Ophthalmology - Flaum Eye Institute


David M. Kleinman, MD, MBA, ...

www.reviewofophthalmology.com, $reference.date [cached]

David M. Kleinman, MD, MBA, Rocherster, N.Y., and David N. Zacks, MD, PhD, Ann Arbor, Mich.

...
Dr. Kleinman is a part-time associate professor of ophthalmology at the Flaum Eye Institute at the University of Rochester where he specializes in the medical and surgical care of patients with retinal disease. He has spent more than 10 years working in retinal pharmaceutical development and currently serves as the chief medical officer at ONL Therapeutics Inc.


David M. Kleinman, M.D., ...

www.onltherapeutics.com, $reference.date [cached]

David M. Kleinman, M.D., M.B.A., Chief Medical Officer

Dr. Kleinman is a board-certified ophthalmologist with fellowship training in vitreoretinal surgery and more than ten years experience in venture creation and ophthalmic drug and device development. He currently serves as a part-time associated professor ophthalmology at the Flaum Eye Institute at the University of Rochester, where he specializes in the medical and surgical care of patients with retinal disease. David is the former chief of ophthalmology at Denver Health Medical Center, where he also served as an assistant professor of ophthalmology at the Rocky Mountain Lions Eye Institute.
In 2003, he helped found MacuSight, a venture capital backed retinal drug development company, where served as consulting medical director. In his role with MacuSight, David assisted in guiding the company through Series A financing, pre-clinical studies, initial investigational new drug (IND) submission, and Phase I/II clinical development. MacuSight's assets were acquired by Santen in 2010. He holds a bachelor's degree from Brown University, an MBA from the Simon School of Business, and an M.D. with honors from the University of Colorado School of Medicine.


The company has appointed David ...

www.onltherapeutics.com, $reference.date [cached]

The company has appointed David Kleinman, M.D. as chief medical officer and Linda Johnson as senior vice president of operations, bringing significant industry experience to ONL in the area of ocular drug development.

...
Dr. Kleinman is also a retina specialist and has spent over ten years in venture creation and ophthalmic drug and device development. He currently serves as part-time associate professor of ophthalmology on the retina service at the Flaum Eye Institute at the University of Rochester. Previously, Dr. Kleinman helped found MacuSight, a venture capital backed retinal drug development company, where he served as consulting medical director. In his role with MacuSight David assisted in guiding the company through Series A financing, pre-clinical studies, investigational new drug (IND) submission, and Phase I/II clinical development. David has extensive experience consulting for both small and large ophthalmic companies in clinical trial design and execution, regulatory interaction, drug safety monitoring, and the evaluation and advancement of novel ophthalmic technology.

Similar Profiles

Other People with this Name (2,315)

Other people with the name Kleinman

Scott Kleinman
InteliSecure

Paul Kleinman
Kleinman Graham

Scott Kleinman
Operations Management International , Inc.

Alaina Kleinman
Edelman Inc

Elliott Kleinman
Hebrew Union College

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory